Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zogenix, Battelle agree to work toward out-licensing needle-free injection platform

This article was originally published in Scrip

Executive Summary

Zogenix has signed a letter of intent with Battelle, the research and development organisation, for a collaboration aimed at developing and commercialising Zogenix’ needle-free DosePro drug delivery technology in fields outside the firm’s core therapeutic areas which consist of CNS disorders and pain. The other uses could potentially be for delivery of high-dose biologics, which are either pipeline products or currently marketed products. For currently marketed drugs, the technology could form part of a life cycle management strategy.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts